







an Open Access Journal by MDPI

Emerging Pharmaceutical Therapeutics for Neglected Tropical Diseases

Guest Editors:

Prof. Dr. Achim Hoerauf

Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany

Prof. Dr. Marc Hübner

Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany

Deadline for manuscript submissions:

closed (30 April 2024)

Message from the Guest Editors

Dear Colleagues,

In the recent past, several new candidates were identified for neglected tropical diseases (NTDs). While the first drugs were registered, e.g., fexinidazole for sleeping sickness or miltefosin and paromomycin combination leishmaniasis in Africa, more drug candidates are in development (e.g., phase 2b/3 studies for leishmaniasis, Chagas disease or myecetoma). However, for some NTDs, the pipeline of new drug candidates is not well equipped. and only a few candidates are within phase 1 or 2 clinical trials (e.g., for onchocerciasis). In the present Special Issue, we ask authors to submit original research and review articles that relate to drug candidates for NTDs with special emphasis on their formulation, dosage form, drug delivery and pharmacokinetics, etc., as is the scope of the journal.

Prof. Dr. Achim Hoerauf Prof. Dr. Marc Hübner *Guest Editors*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us